anti-CD19 CAR γδT-cells

Anti-CD19 CAR γδT-cells are genetically engineered T cells expressing chimeric antigen receptors (CARs) specific for the CD19 antigen, which is highly expressed on B-cell malignancies. These cells are created using γδ T cells—a subset of T lymphocytes with unique antigen recognition properties distinct from conventional αβ T cells. The engineering process involves transducing γδ T cells (most commonly Vγ9Vδ2 or Vδ1 subtypes) with a CAR construct (typically using a single-chain variable fragment recognizing CD19, often in combination with costimulatory domains such as CD28 or 4-1BB) to direct their cytotoxic activity against CD19-positive tumor cells. Unlike traditional CAR-T therapies which use αβ T cells, γδ CAR-T cells combine CAR-dependent cytotoxicity with innate-like anti-tumor recognition, broad antigen detection (independent of MHC), and often greater potential for allogeneic, off-the-shelf use. These cells show specific and enhanced cytotoxicity against CD19-positive tumor cells in vitro and in vivo, with added benefit of cross-presenting tumor antigens to other immune cells. They are being explored primarily for B-cell hematologic malignancies such as B-cell lymphoma and leukemia. The clinical research is largely at the early phase (e.g., Phase 1) and preclinical stages[1][2][3][4][7].

Other names

CD19 CAR γδT-cellsanti-CD19 chimeric antigen receptor gamma delta T-cellsanti-CD-19 chimeric antigen receptor gamma delta T-cellsanti-CD 19 chimeric antigen receptor gamma delta T-cellsCD19 CAR gamma delta T cellsCD-19 CAR gamma delta T cellsCD 19 CAR gamma delta T cells